SZN-413, a FZD4 Agonist, as a Potential Novel Therapeutic for the Treatment of Diabetic Retinopathy.
Nguyen H, Chen H, Vuppalapaty M, Whisler E, Logas KR, Sampathkumar P, Fletcher RB, Sura A, Suen N, Gupta S, Lopez T, Ye J, Tu S, Bolaki M, Yeh WC, Li Y, Lee SJ.
Nguyen H, et al. Among authors: bolaki m.
Transl Vis Sci Technol. 2022 Sep 1;11(9):19. doi: 10.1167/tvst.11.9.19.
Transl Vis Sci Technol. 2022.
PMID: 36149648
Free PMC article.